FDA approves Alcon’s new IOL to treat presbyopia, astigmatism

Correcting presbyopia and astigmatism, with one lens, at the time of cataract surgery is a great benefit to patients.
Correcting presbyopia and astigmatism, with one lens, at the time of cataract surgery is a great benefit to patients. | File photo
Alcon, a division of Novartis that specializes in eye care, has received approval from the U.S. Food and Drug Administration for AcrySof IQ ReSTOR +3.0D Multifocal Toric Intraocular Lens (IOL), which was developed to treat presbyopia and pre-existing corneal astigmatism.
“The AcrySof IQ ReSTOR +3.0D Multifocal Toric IOL is an important addition to our market-leading IOL portfolio, and broadens our offering of presbyopia- and astigmatism-correcting lenses to meet the different visual needs of patients,” Alcon Region President for North America Sergio Duplan said. “We are committed to delivering ongoing innovation that enables surgeons to provide the best possible outcome for their patients.”
The IOL is already available in the European Union, Australia, Canada and other countries in Central and South America and Asia.
“Correcting presbyopia and astigmatism, with one lens, at the time of cataract surgery is a great benefit to patients and can improve patient satisfaction,” Associated Eye Care Medical Director Dr. Stephen Lane said. “The introduction of this advanced technology IOL gives us an additional treatment option to help reduce dependence on spectacles for patients with astigmatism.”
Want to get notified whenever we write about Alcon ?
Next time we write about Alcon, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Alcon 6201 South Fwy Fort Worth, TX - 76134